Biotech Values

[DewDiligence]

Doesn’t the Seattle Times article worry you even a little vis-à-vis DNDN? To wit:

1. Dr. Celestia Higano, a clinician in the 9902a trial, admits to selling clinical data to hedge funds.

2. DNDN has an enormous short position.

3. DNDN steadfastly refuses to disclose key details of the 9902a data such as the p-value, Hazard Ratio, or three-year survival rate.

I’d be a little nervous myself if I were still long. JMHO. Dew